1E Therapeutics is a drug-development company creating RNA-targeting therapeutics based on a proprietary drug-design platform. 1E's process has proven able to develop drugs that address chronic life-threatening indications as well as emerging and evolving pathogens. 1E already has lead compounds that address a wide array of indications in oncology, age-related diseases, immunology, anti-microbial resistance, viral infections, and orphan neurological disorders.